BigHat Raises $75M to Scale AI Protein Design Platform
BigHat Biosciences has raised $75 million in Series C financing as the clinical-stage biotechnology company expands an AI-native platform that combines protein design models with autonomous laboratory experimentation. The company says the funding will support its data-generation infrastructure and advance AI-designed therapeutics, including BHB810, which entered Phase 1 clinical testing in September 2026. The next…
